Latest Medtech News
OSSTEC, a London-based orthopedic company developing 3D-printed cementless joint replacement implants, has closed $8 million to fund the first U.S. surgical cases of ASCENT, its cementless, fixed-bearing partial knee system. EMBRYO Ventures led the round, with Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures taking part.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
The money will take ASCENT and its CLARITY instrumentation through FDA clearance to first-in-human procedures in the U.S., planned for the first half of 2027. It also covers training and support for OSSTEC’s surgeon faculty at leading partial knee centers, following the company’s U.S. launch earlier this year. Neither product is cleared by the FDA or available for sale in the U.S.
OSSTEC points to a gap in current practice: about half of knee replacement patients are suitable for a partial knee, yet only around 10% receive one. The company says cement adds time and complexity in the operating room, and that cementless fixation reduces loosening, a leading cause of revision. ASCENT uses a 3D-printed biomimetic fixation platform built on more than a decade of research into osseointegration.
OSSTEC is also expanding a pipeline of cementless applications beyond the partial knee and evaluating integration with robotic surgery platforms, a space where Enovis recently agreed to acquire eCential Robotics. CEO Max Munford said the financing “moves our focus from preparation to patients.”
